Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Hyundai Motor Company

Kia Motors Corporation

Inje University Industry-Academic Cooperation Foundation

Other

Industry-University Cooperation Foundation Hanyang University

Inalfa Roof Systems Group B.v.

Hanmi Holdings Co., Ltd.

Dae Jin Kim

Jin Young Kim

Se Chang Kwon

Sung Youb Jung

Sung Min Bae

Sung H Hong

Jong Soo Lee

In Young Choi

Myung Hyun Jang

Sung Hee Park

Young Eun Woo

Young Min Kim

Gwan Sun Lee

Hyun Uk Kim

Chang Ki Lim

Min Young Kim

Su Yeon Park

Young Jin Park

Eun Jung Kim

Jong-Soo Lee

Hyung Kyu Lim

Jin Sun Kim

Ji Young Song

Jung Kuk Kim

Yong Ho Heo

Hyun Kyung Lee

Yeong Seok Kim

Ga Bin Park

Dae Young Hur

Jong Min Lee

Sang Hyun Lee

Jae Hyuk Choi

Seung Won Choi

Ju Hwan Kim

Seung Su Kim

Dae Hae Song

Jae Wook Yang

Sang Youn Hwang

Ling Ai Shen

Yong Ho Huh

Byung Sun Lee

Hyun Sik Yun

Min Jae Lee

Yong Gyu Jung

Kwang Young Park

Heung Seop Ahn

Joo Hoon Lim

Hwa Kyong Sung

Kyung Wook Baek

Sung In Lim

Seong Han Kim

Zhongfeng Zhang

Cheong Byeol Shin

Sun Jin Moon

Jong-soo Lee

Mi Yong Lee

Cheol Yong Cha

Seong Hyun Son

Young Gil Ju

Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.

Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor

Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.

Polyethylene glycol derivative and use thereof

One aspect of the present invention provides a compound in which a functional group capable of binding to a globulin Fc region or a physiologically active polypeptide is introduced at one end of a non-peptidic polymer and a functional group capable of a click reaction is introduced at the other end; a polypeptide conjugate in which a physiologically active polypeptide binds to one end of the compound; a physiologically active polypeptide conjugate in which a physiologically active polypeptide and an immunoglobulin Fc region bind to both ends thereof by using the compound as a linker; and methods for preparing the same compound, polypeptide conjugate, and physiologically active polypeptide conjugate.

Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate

The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof

The present invention relates to polyethylene glycol derivatives and use thereof.

A method for preparing a conjugate of a physiologically active polypeptide and a non-peptide polymer by linking physiologically active polypeptide with non-peptide polymer through a covalent bond using an organic solvent is provided. A method for preparing a physiologically active polypeptide complex by linking the conjugate with a carrier is provided. The complex shows improved in vivo duration and stability of the physiologically active polypeptide. The method can prepare the conjugate at a lower production cost, and the resulting conjugate shows an extension of in vivo activity at a relatively high level and significantly increase in the blood half-life.

Method for preparing physiologically active polypeptide complex

Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Protein complex by use of a specific site of an immunoglobulin fragment for linkage

A vehicle wheel having a suspension and a steering device is capable of not only simplifying a driving system but also reducing the number of parts and reducing weight. The vehicle wheel includes a suspension combined with a damper and a spring in a housing of a stator of an in-wheel motor embedded in each wheel of a vehicle and a steering device directly connected to the suspension.

Vehicle wheel having a suspension and a steering device

Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Disclosed is a method for the preparation of a complex in which a physiologically active polypeptide is covalently bonded to an immunoglobulin constant region via a non-peptidyl linker. The method is characterized by the employment of a reducing agent, by which conventional problems of low production yield and modification of the polypeptide can be overcome. The physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be produced with high purity and yield as well as at low cost. Thus, the method is industrially useful. Moreover, by exhibiting a prolonged action profile, the physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be effectively used for developing long-acting formulations of physiologically active polypeptides which have improved drug compliance.

Process for preparation of physiologically active polypeptide complex

Provided is a method of preparing a physiologically active polypeptide conjugate, in which a physiologically active polypeptide and a non-peptidyl polymer are linked to each other via a covalent bond. The method is to improve an overall yield of the physiologically active polypeptide conjugate by improving a reaction of the non-peptidyl polymer and the physiologically active polypeptide, and particularly, the method is to prepare a physiologically active polypeptide conjugate in a high yield by performing a two-step reaction through selective precipitation. The preparation method of the present invention is used to produce a non-peptidyl polymer-physiologically active polypeptide conjugate and a physiologically active polypeptide-physiologically active carrier conjugate in a high yield, and therefore, the method may be used in the development of long-acting formulations of various peptide drugs which maintain in vivo activity at a relatively high level and have remarkably increased blood half-life.

Method of preparing physiologically active polypeptide conjugate

The present invention relates to a conjugate in which an immunoglobulin Fc region is linked to therapeutic enzymes through a non-peptide polymer linkage moiety, and more specifically, to a conjugate in which a non-peptide polymer linkage moiety is specifically linked to an immunoglobulin Fc, a method of preparing the same, and a composition comprising the same.

Conjugate of therapeutic enzymes

A reconfigurable radio equipment may include at least two radio computers; a communication services layer comprising an administrator, a mobility policy manager, a networking stack, and a monitor; and a routing entity performing communications among the at least two radio computers and the communication services layer.

Reconfigurable radio equipment having multiple radio computers, and operation method for the same

The present invention relates to insulin and/or an insulin analogue conjugate, and a use thereof, wherein the insulin and/or insulin analogue have improved in vivo durability and stability by linking the same with an Fc region of immunoglobulin. The insulin and/or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and/or insulin analogue conjugate of the present invention are long-acting formulations of insulin and/or the analogue thereof, in which serum half-life is remarkably increased, and therefore, the present invention provides remarkable insulin and/or an insulin analogue conjugate, which do not induce hypoglycemia, a drawback of insulin treatment.

Long-acting insulin or insulin analogue conjugate

Growing community of inventors

Seocho-gu, South Korea

Dae Jin Kim